Polyrizon Ltd.

Polyrizon Ltd. has issued a Notice and Proxy Statement for its Annual General Meeting of Shareholders scheduled for July 13, 2026. Key agenda items include the re-election of two directors, approval of an amended compensation policy for executives and directors, and the grant of equity awards to directors and key officers. The company also proposes the re-appointment of Deloitte as its independent auditor for the year ending December 31, 2026. Shareholders of record as of June 15, 2026, are entitled to vote.

Polyrizon Ltd. announced it has secured agreements with two additional U.S. clinical sites, bringing the total to three major contracted sites for its upcoming NASARIX™ (PL-14) clinical study. These sites are considered the largest and most strategically important, expected to drive high patient enrollment for the multi-center trial evaluating the NASARIX™ Allergy Blocker for seasonal allergic rhinitis. The company believes this rapid expansion of its clinical site network positions it strongly for efficient patient recruitment and timely study execution.

Polyrizon Ltd. announced it has signed agreements with two additional U.S. clinical sites for its upcoming NASARIX (PL-14) clinical study, bringing the total to three major contracted sites. These sites are strategically important and are expected to contribute significantly to patient enrollment. The study will evaluate the safety, tolerability, and efficacy of the NASARIX Allergy Blocker in patients with seasonal allergic rhinitis, marking strong execution of the company's clinical plan.

Polyrizon Ltd. announced an extension of its non-binding Memorandum of Understanding (MOU) with Arrow Aviation Ltd. The exclusivity period and Initial Negotiation Period under the MOU have been extended to June 30, 2026. This MOU pertains to Polyrizon's proposed acquisition of a 51% stake in Arrow Aviation, with all other terms remaining unchanged.

Polyrizon Ltd. announced the appointment of Mr. Ami Oren as a Class I director, effective May 14, 2026. Mr. Oren, 51, is an entrepreneur with over two decades of experience in founding, scaling, and managing consumer-facing businesses. He previously owned and founded Hummus Ami, a food and hospitality business in Israel, which he successfully sold. Mr. Oren's expertise includes operational leadership, P&L management, and cost control.

Polyrizon Ltd. announced a significant step towards human clinical trials by securing its first U.S. clinical site for the NASARIX™ (PL-14) Allergy Blocker. The company signed a Clinical Trial Agreement (CTA) with a Texas-based research site specializing in allergy studies. This multi-center study will assess the safety, tolerability, and efficacy of the investigational intranasal spray in patients with seasonal allergic rhinitis, aligning with Polyrizon's broader regulatory strategy.

Polyrizon Ltd. announced the signing of its first Clinical Trial Agreement (CTA) with a U.S.-based clinical research site in Texas. This agreement marks a significant step towards initiating the clinical program for its NASARIXTM (PL-14) Allergy Blocker. The planned multi-center study will assess the safety, tolerability, and efficacy of the investigational nasal spray in patients with seasonal allergic rhinitis, adhering to international Good Clinical Practice (GCP) standards.

Polyrizon Ltd. announced the submission of amended claims for its U.S. patent application for its proprietary intranasal drug delivery platform. This expansion broadens the scope of protection to include drug delivery systems and methods of use, in addition to the core mucoadhesive composition. The company believes this will enhance the value and applicability of its platform by improving drug effectiveness through increased residence time and mucosal interaction, aligning with its strategy to strengthen its intellectual property portfolio.

Polyrizon Ltd. detailed its indemnification policies for directors and officers under Israeli law, noting the SEC's stance on enforceability for Securities Act liabilities. The company also reported several recent securities sales, including a significant private placement on March 31, 2025, which raised approximately $17.0 million. Further capital was raised through registered direct offerings in December 2025 and April 2026, along with a concurrent private placement in April 2026.

Polyrizon Ltd. announced the filing of a European patent application for its breakthrough drug delivery platform. This strategic move aims to protect the company's innovative technology in a key international market, potentially enhancing its intellectual property portfolio and future commercial prospects.